4D Molecular Therapeutics (FDMT) EBIT Margin (2020 - 2025)
Historic EBIT Margin for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to 67983.33%.
- 4D Molecular Therapeutics' EBIT Margin rose 16364166700.0% to 67983.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 191982.5%, marking a year-over-year increase of 7984645600.0%. This contributed to the annual value of 507678.38% for FY2024, which is 5071337300.0% down from last year.
- Latest data reveals that 4D Molecular Therapeutics reported EBIT Margin of 67983.33% as of Q3 2025, which was up 16364166700.0% from 396373.33% recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' EBIT Margin ranged from a high of 192905.26% in Q4 2023 and a low of 5611700.0% during Q4 2024
- In the last 5 years, 4D Molecular Therapeutics' EBIT Margin had a median value of 13446.03% in 2023 and averaged 475592.34%.
- In the last 5 years, 4D Molecular Therapeutics' EBIT Margin crashed by 2000000000bps in 2024 and then soared by 2000000000bps in 2025.
- Quarter analysis of 5 years shows 4D Molecular Therapeutics' EBIT Margin stood at 26917.39% in 2021, then surged by 91bps to 2303.13% in 2022, then surged by 8476bps to 192905.26% in 2023, then tumbled by -3009bps to 5611700.0% in 2024, then soared by 99bps to 67983.33% in 2025.
- Its EBIT Margin was 67983.33% in Q3 2025, compared to 396373.33% in Q2 2025 and 383007.14% in Q1 2025.